188 related articles for article (PubMed ID: 29529282)
1. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.
Hecht R; Hiebert L; Spearman WC; Sonderup MW; Guthrie T; Hallett TB; Nayagam S; Razavi H; Soe-Lin S; Vilakazi-Nhlapo K; Pillay Y; Resch S
Health Policy Plan; 2018 May; 33(4):528-538. PubMed ID: 29529282
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
3. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
4. Estimating a cost-effectiveness threshold for health care decision-making in South Africa.
Edoka IP; Stacey NK
Health Policy Plan; 2020 Jun; 35(5):546-555. PubMed ID: 32125375
[TBL] [Abstract][Full Text] [Related]
5. Triple return on investment: the cost and impact of 13 interventions that could prevent stillbirths and save the lives of mothers and babies in South Africa.
Michalow J; Chola L; McGee S; Tugendhaft A; Pattinson R; Kerber K; Hofman K
BMC Pregnancy Childbirth; 2015 Feb; 15():39. PubMed ID: 25879579
[TBL] [Abstract][Full Text] [Related]
6. Requirements for global elimination of hepatitis B: a modelling study.
Nayagam S; Thursz M; Sicuri E; Conteh L; Wiktor S; Low-Beer D; Hallett TB
Lancet Infect Dis; 2016 Dec; 16(12):1399-1408. PubMed ID: 27638356
[TBL] [Abstract][Full Text] [Related]
7. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
Ward JW; Hinman AR
Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
[TBL] [Abstract][Full Text] [Related]
8. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
[TBL] [Abstract][Full Text] [Related]
9. Saving newborn lives in Asia and Africa: cost and impact of phased scale-up of interventions within the continuum of care.
Darmstadt GL; Walker N; Lawn JE; Bhutta ZA; Haws RA; Cousens S
Health Policy Plan; 2008 Mar; 23(2):101-17. PubMed ID: 18267961
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning.
Trickey A; Hiebert L; Perfect C; Thomas C; El Kaim JL; Vickerman P; Schȕtte C; Hecht R
Liver Int; 2020 Feb; 40(2):286-297. PubMed ID: 31454466
[TBL] [Abstract][Full Text] [Related]
11. Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
Nayagam S; Chan P; Zhao K; Sicuri E; Wang X; Jia J; Wei L; Walsh N; Rodewald LE; Zhang G; Ailing W; Zhang L; Chang JH; Hou W; Qiu Y; Sui B; Xiao Y; Zhuang H; Thursz MR; Scano F; Low-Beer D; Schwartländer B; Wang Y; Hallett TB
Clin Infect Dis; 2021 Mar; 72(5):743-752. PubMed ID: 32255486
[TBL] [Abstract][Full Text] [Related]
12. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
14. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group.
Kaur S; Rybicki L; Bacon BR; Gollan JL; Rustgi VK; Carey WD
Hepatology; 1996 Nov; 24(5):979-86. PubMed ID: 8903363
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
[TBL] [Abstract][Full Text] [Related]
16. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
[TBL] [Abstract][Full Text] [Related]
17. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
[TBL] [Abstract][Full Text] [Related]
18. Modelling the Cost-Effectiveness of Hepatitis A in South Africa.
Patterson J; Cleary S; Norman JM; Van Zyl H; Awine T; Mayet S; Kagina B; Muloiwa R; Hussey G; Silal SP
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400100
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of the societal costs of hepatitis B in South Korea.
Yang BM; Paik SW; Hahn OS; Yi DH; Choi MS; Payne S
J Gastroenterol Hepatol; 2001 Mar; 16(3):301-8. PubMed ID: 11339422
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
